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Introduction {#acn3560-sec-0005}
============

The 88 kDa progranulin and its 6 kDa processed products (granulins) represent a class of secreted proteins with diverse functions peripherally and in the brain. Granulins and progranulin have been implicated as potent immunomodulators and cell‐cycle regulators. In the CNS, progranulin expression increases with age in both neurons and microglia, and plays a role in neurite outgrowth, synapse modification, and the prevention of neuronal apoptosis.[1](#acn3560-bib-0001){ref-type="ref"}, [2](#acn3560-bib-0002){ref-type="ref"}, [3](#acn3560-bib-0003){ref-type="ref"}, [4](#acn3560-bib-0004){ref-type="ref"} This neuroprotective function is highlighted by the relationship between progranulin and neurodegenerative disease; heterozygous loss‐of‐function mutations in the gene encoding progranulin (*GRN*) cause frontotemporal dementia (FTD),[5](#acn3560-bib-0005){ref-type="ref"}, [6](#acn3560-bib-0006){ref-type="ref"} and a common rs5848 allele in the 3′UTR of *GRN* has been associated with both decreased serum and brain progranulin expression levels and increased risk of developing Alzheimer\'s disease (AD).[7](#acn3560-bib-0007){ref-type="ref"}, [8](#acn3560-bib-0008){ref-type="ref"}, [9](#acn3560-bib-0009){ref-type="ref"} Additionally, misregulation of progranulin expression has been implicated in parkinsonism, neuronal ceroid lipofuscinosis, and other neuropsychiatric disorders.[10](#acn3560-bib-0010){ref-type="ref"}, [11](#acn3560-bib-0011){ref-type="ref"}

Mutations in the *GRN* gene may contribute to the risk of developing AD.[8](#acn3560-bib-0008){ref-type="ref"}, [12](#acn3560-bib-0012){ref-type="ref"} Additionally, progranulin localizes at the margins of amyloid plaques in both mouse and human postmortem brain tissue, and increased progranulin mRNA levels have been reported in the brains of multiple AD‐mouse models.[13](#acn3560-bib-0013){ref-type="ref"} Overexpression of progranulin in these models has been shown to slow plaque deposition and cognitive decline.[14](#acn3560-bib-0014){ref-type="ref"}, [15](#acn3560-bib-0015){ref-type="ref"} Taken together, these data suggest a direct role of progranulin in AD pathogenesis. Previous studies examining protein levels in peripheral blood failed to detect a relationship between peripheral progranulin protein levels and AD status.[16](#acn3560-bib-0016){ref-type="ref"} We first observed a relationship between *GRN* mRNA levels and AD status in a small patient series,[17](#acn3560-bib-0017){ref-type="ref"} but no study to date has conclusively shown a connection between progranulin expression and sporadic AD.

Early detection of AD has increasingly become a focus of the biomedical community, as future treatment modalities will likely hinge on slowing or preventing neurodegeneration before it has occurred. As such, mild cognitive impairment (MCI)--defined by focal memory or executive function deficits not explained by age, without dementia or loss of day‐to‐day function -- has become a major focus of study.[18](#acn3560-bib-0018){ref-type="ref"} MCI patients convert to AD at a rate of 10--15% per year.[19](#acn3560-bib-0019){ref-type="ref"}, [20](#acn3560-bib-0020){ref-type="ref"} However, the majority of MCI patients will not transition to dementia, and some may display spontaneous improvement.[19](#acn3560-bib-0019){ref-type="ref"} Currently, estimates of hippocampal or entorhinal cortex volume coupled with cognitive function testing are the best predictors of disease transition.[20](#acn3560-bib-0020){ref-type="ref"}, [21](#acn3560-bib-0021){ref-type="ref"} However, reconstructive MRI imaging is expensive and not easily transferable to community hospitals. Thus, further work is needed to uncover peripheral blood markers of MCI.

We studied *GRN* expression levels in peripheral blood in a large patient series with AD and MCI, and asymptomatic controls, as well as in multiple datasets from the literature. We correlated *GRN* mRNA levels with demographic characteristics, disease status, genetic risk factors, methylation at the *GRN* locus, and progranulin protein levels as assayed by ELISA.

Material and Methods {#acn3560-sec-0006}
====================

Subjects and samples {#acn3560-sec-0007}
--------------------

This study received prior approval from the Institutional Review Board at the University of California San Francisco, and informed consent was obtained from subjects prior to study enrollment and sample collection.

### UCSF‐MAC cohort {#acn3560-sec-0008}

In this study, 530 patients clinically diagnosed as either AD, MCI, or unaffected controls were enrolled at the UCSF‐MAC between 2006 and 2016. MRI and Amyloid PET imaging were not uniformly performed to support diagnosis.

Peripheral blood from each subject was collected in Paxgene tubes and kept in ice prior to total RNA isolation. RNA extraction was performed, using the RNeasy QIAcube extraction kit (Qiagen) and RNA quantity was determined, using a Nanodrop instrument (Nanodrop Technologies). RNA quality was assessed with the Agilent Bioanalyzer (Agilent Technology) and samples with an RNA Integrity Number (RIN) \<7 were excluded. RNA libraries were hybridized to Illumina HumanHT‐12 V4.0 microarrays at the UCLA Neuroscience Genomics Core. Microarray slides were scanned and signal processed using Illumina BeadStation and the BeadStudio software package in preparation for subsequent analysis. Here, 22 samples were ultimately excluded due to poor RIN or were detected as outliers (described below) for a final cohort size of *n* = 508.

### AddNeuroMed cohort {#acn3560-sec-0009}

The AddNeuroMed cohort 1 is publicly available in the Gene Expression Omnibus (GEO) repository (Accession: GSE63060).[22](#acn3560-bib-0022){ref-type="ref"} Briefly, this patient cohort is composed of 329 samples diagnosed as AD, MCI, or control with RNA hybridized to Illumina HumanHT‐12 V3.0 microarrays. Ultimately 21 outliers were removed and an additional 34 samples were dropped to correct for an age confound (described below) for a final cohort size of *n* = 274.

### ADNI {#acn3560-sec-0010}

Data used in this manuscript were obtained from the Alzheimer\'s Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). The ADNI was launched in 2003 under the direction of Principal Investigator Dr. Michael W. Weiner, MD to interrogate whether biological markers and clinical assessment can be combined to measure the progression of MCI and early AD.

The ADNI_Gene_Expression_Profile dataset is made available from the Alzheimer\'s Disease Neuroimaging Initiative (ADNI) repository. Samples were prepared as described (<http://adni.loni.usc.edu/wp-content/uploads/2008/07/ADNI_GO_Procedures_Manual_06102011.pdf>). Briefly, 811 patients in the ADNI cohort were categorized as Control, Early MCI, Late MCI, or AD using published clinical criteria. Total RNA was extracted and hybridized to an Affymetrix Human Genome U219 array and scanning and signal extraction were performed, using the Affymetrix GeneTitan system. After quality control, outlier removal, and stratification for an age confound (described below), the final processed cohort was *n* = 617.

### San Antonio family heart study {#acn3560-sec-0011}

The San Antonio Family Heart Study (SAFHS) dataset[23](#acn3560-bib-0023){ref-type="ref"} is publicly available through ArrayExpress (<http://www.ebi.ac.uk/arrayexpress>) under the accession E‐TABM‐305. This cohort is composed of 1240 peripheral blood lymphocyte samples hybridized to Illumina Human‐6 v1 Expression BeadChip microarrays. Following outlier removal, we stratified this dataset to remove collinearity between sex and smoking status (described below). We then excluded all samples below 30 years old to match the age of our other datasets. The final processed cohort was *n* = 543.

Genotyping {#acn3560-sec-0012}
----------

Subjects in the UCSF‐MAC cohort had genomic DNA isolated from peripheral blood following standard procedures. APOE and GRN rs5848 genotyping were carried out by real‐time PCR on an Applied Biosystems 7900HT Real Time PCR machine (Applied Biosystems, Foster City, CA), using Taqman SNP Genotyping Assays (\#C\_\_\_7452046_20, C\_\_\_3084793_20, and C\_\_\_\_904973_10 for rs5848, rs429358, and rs7412, respectively). Assays were run in triplicate. The SDS version 2.3 software was used to analyze the raw data and to call the genotypes.

Array processing {#acn3560-sec-0013}
----------------

Microarray raw signal processing for the UCSF‐MAC cohort was performed using the *lumi* package.[24](#acn3560-bib-0024){ref-type="ref"} First, within‐sample raw gene expression intensities were normalized using variance‐stabilized transformation (VST)[25](#acn3560-bib-0025){ref-type="ref"} and interarray normalization was performed with robust spline normalization. Probes with a detection score below standard threshold (*P* = 0.01) for all samples were dropped along with probes not annotated within the lumiHumanAll.db database. Next, ComBat from the *sva* package[26](#acn3560-bib-0026){ref-type="ref"} was used to perform batch correction. Outliers were removed using a connectivity Z‐score (threshold \> 2) calculated using the *fundamentalNetworkConcepts* function from the *WGCNA* package.[27](#acn3560-bib-0027){ref-type="ref"} The AddNeuroMed cohort was processed using the same pipeline except that log2 normalization was used instead of VST because some quality control information was missing from the raw data.

The raw data for the ADNI dataset is not publicly available. Therefore, we performed analysis on preprocessed array data which were normalized, using standard Robust‐Multi‐Array Averaging from the *affy* package.[28](#acn3560-bib-0028){ref-type="ref"} We subsequently excluded 33 outliers using connectivity *Z*‐scores (threshold \> 2) and 11 samples with a RIN \< 7, and performed batch correction using ComBat. Probes were annotated using the Affymetrix *hgu219.db* database from BioConductor. The SAFHS cohort was analyzed using the same pipeline as the UCSF‐MAC cohort except for batch correction, which was not performed as batch information was not available.

Removal of confounding covariates {#acn3560-sec-0014}
---------------------------------

We used linear modeling and *G*‐tests[29](#acn3560-bib-0029){ref-type="ref"} to determine if age or sex were collinear with diagnosis using a significance threshold of *P* \< 0.05. When significant collinearity was observed, samples were stratified, using a randomized nonbiased approach to drop samples until collinearity was no longer observed. Thus, final analysis was run on cohorts with age, sex, and diagnosis verified as independent variables. For the SAFHS dataset, sample stratification was used to remove collinearity between sex and smoking status.

Statistical analysis {#acn3560-sec-0015}
--------------------

Intensity values for probes querying *GRN* expression were collected from each platform. Each *GRN* probe was verified for every cohort by ensuring that average expression intensity was greater than the 60th percentile of all detected probes -- no probes were dropped. For Illumina platforms, two progranulin probes were identified: AAGGCTCGATCCTGCGAGAAGGAAGTGGTCTCTGCCCAGCCTGCCACCTT (Probe 1, mapping to exon 11) and GGCCTTCCCTGTCAGAAGGGGGTTGTGGCAAAAGCCACATTACAAGCTGC (Probe 2, mapping to the 3′UTR). Neither location harbors known SNPs or InDels at a high population frequency (\>1:1000). As probes were correlated (*r* ^2^ = 0.75), we reported only probe 1, which also had higher mean expression values. Linear models were used to assess significance of diagnosis or genotype with gender, age, and interactions (when appropriate) included as covariates. An *F*‐test was used to assess significance of categorical predictors with more than two groups, and Welch\'s *T*‐test was used for continuous predictors or categorical predictors with two groups. Post hoc pairwise testing was done using Tukey\'s test with a significance threshold of *P* \< 0.05. The Wilcoxon rank sum test was used in a case of small, nonnormal sample.

Quantification of progranulin protein by ELISA {#acn3560-sec-0016}
----------------------------------------------

Progranulin protein in human plasma and cerebrospinal fluid (CSF) was quantified by A&G Pharmaceutical Inc. (Columbia, MD) using their Progranulin (GP88/PGRN) ELISA, which detects full‐length progranulin in both biofluids. The detection limit of this assay is 100 pg/mL with a working range up to 20 ng/mL. Assay details have been described previously.[30](#acn3560-bib-0030){ref-type="ref"}, [31](#acn3560-bib-0031){ref-type="ref"}, [32](#acn3560-bib-0032){ref-type="ref"} Briefly, a subset of patients enrolled in the UCSF‐MAC cohort underwent peripheral blood draws (*n* = 266) and/or lumbar puncture (*n* = 80) during multiple follow‐up visits. Each sample was run in duplicate and normalized against a recombinant progranulin standard and two reference serum samples. A coefficient of variation score (SD/mean\*100) was calculated for every sample. The 11 plasma samples with a coefficient of variation \>15% were dropped as a quality control measure. Patients who underwent multiple draws had their plasma or CSF PGRN values averaged. Outliers were removed using the R *boxplot* function. Statistical analysis was done using the same models and tests as described for gene expression.

Methylation {#acn3560-sec-0017}
-----------

DNA was extracted from peripheral blood using standard methods. DNA methylation was quantified using the Illumina Human Methylation 450K microarray. Preprocessing was run with the *RnBeads* package[33](#acn3560-bib-0033){ref-type="ref"}, using the default options for quality control. Background correction was performed with the normal exponential convolution, using out‐of‐band probes (noob) method,[34](#acn3560-bib-0034){ref-type="ref"} and arrays were normalized using beta mixture quantile dilation (BMIQ).[35](#acn3560-bib-0035){ref-type="ref"} The normalized data was corrected for batch effect using the parametric empirical Bayes method from ComBat.[26](#acn3560-bib-0026){ref-type="ref"} The *RnBeads* package was also used to extract *GRN* promoter methylation *β*‐values, which were computed by averaging the *β*‐values of all 10 probes from 1.5 kb upstream to 0.5 kb downstream of the transcription start site. *RNBeads* was similarly used to extract gene body methylation, again by averaging the *β*‐values of all 10 probes from the transcription start site to the end of the gene.

Results {#acn3560-sec-0018}
=======

Demographic and diagnostic determinants of GRN expression {#acn3560-sec-0019}
---------------------------------------------------------

General characteristics of all processed cohorts (postquality control and confounder stratification) are described in Table [1](#acn3560-tbl-0001){ref-type="table-wrap"}. We first analyzed the UCSF‐MAC cohort (*n* = 508).

###### 

Summary characteristics of four patient cohorts analyzed

  Cohort         Diagnosis   Sample (n)   Male (n)   Female (n)   Mean Age   SD Age
  -------------- ----------- ------------ ---------- ------------ ---------- --------
  UCSF‐MAC       Combined    508          240        268          69.8       10.4
  Control        204         95           109        70.9         11.2       
  MCI            118         61           57         69.7         10.1       
  AD             186         84           102        68.8         9.5        
  AddNeuroMedd   Combined    274          107        167          72.9       5.7
  Control        95          38           57         71.8         5.8        
  MCI            66          32           34         73.1         4.9        
  AD             113         37           76         73.7         5.9        
  ADNI           Combined    617          326        291          73.8       6.5
  Control        240         114          126        74.3         5.6        
  eMCI           159         91           68         73.7         5.8        
  lMCI           178         96           82         73.0         7.2        
  AD             40          25           15         75.6         9.8        
  SAFHS          Combined    543          252        291          49.7       13.5
  Smoker         158         85           73         48.1         12.0       
  Nonsmoker      385         167          218        50.2         13.9       
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First, we assessed the relationship between gene expression, sex, and age, after ensuring no confounding between our predictors. We verified no collinearity between sex and diagnosis in our dataset (*G*‐test, G‐statistic~(2)~ = 1.3, *P* = 0.52) nor between age and diagnosis (*F* ~2,505~ = 2.04, *P* = 0.13). We next fit a linear model for our covariates. We observed that *GRN* mRNA expression levels were significantly higher in males than in females (log~2~ fold‐change \[log~2~FC\] = 0.09, corresponding to a 6% increase, *T*‐statistic = 6.26, *P* = 0.013, Fig. [1](#acn3560-fig-0001){ref-type="fig"}A) across diagnostic categories, and that age was significantly but trivially correlated with progranulin mRNA levels (Pearson\'s *r* ^2^ = 0.008, *P* = 0.04; Fig. [1](#acn3560-fig-0001){ref-type="fig"}B) consistent with previous reports.[11](#acn3560-bib-0011){ref-type="ref"} We next compared *GRN* levels between diagnostic categories (*F* ~2,505~ = 10.41, *P* = 3.7\*10^−5^). Patients diagnosed with AD had a statistically significant increase (log~2~FC = 0.17, corresponding to +13%, Tukey\'s test *P* = 0.00019) in *GRN* mRNA expression compared with controls. We also observed a similar increase (log~2~FC = 0.17, *P* = 0.0012) in the MCI group compared with controls (Fig. [1](#acn3560-fig-0001){ref-type="fig"}C). We observed no significant differences in *GRN* mRNA levels between AD and MCI. When we modeled interactions between sex and diagnosis, as well as age and diagnosis, we did not observe significant effects, arguing against a synergistic relationship between these covariates.

![Effect of demographic characteristics and disease status on peripheral blood *GRN* gene expression. (A) Progranulin gene expression is higher in males than females. UCSF‐MAC cohort, Welch\'s *t*‐test. (B) Progranulin gene expression increases with age across diagnostic categories. UCSF‐MAC cohort, linear regression. (C) Progranulin expression is higher in AD and MCI patients compared with controls. UCSF‐MAC cohort, *F*‐test and analysis of variance (AOV) with Tukey\'s post hoc test. (D) same as (C) in the AddNeuroMed cohort. (E) lack of difference in progranulin expression in AD, early MCI (EMCI), and later MCI (LMCI) patients compared with controls. ADNI cohort, *F*‐test and aov with Tukey\'s post hoc test. General cohort characteristics are described in Table [1](#acn3560-tbl-0001){ref-type="table-wrap"}. (A, C, D, E) standard boxplot representing median and interquartile range (IQR), whiskers represent 1.5 IQR greater or less than the upper and lower quartile. (B) scatterplot with line of best‐fit. \**P* \< 0.05, \*\*\**P* \< 0.001, n.s. *P* \> 0.05.](ACN3-5-616-g001){#acn3560-fig-0001}

We next sought to replicate our findings. We first analyzed the AddNeuroMed Cohort (*n* = 274; Table [1](#acn3560-tbl-0001){ref-type="table-wrap"}). We initially observed collinearity between age and diagnosis (*F* ~2,305~ = 5.81, *P* = 0.003) and therefore stratified and discarded 34 samples until collinearity was no longer significant (*F* ~2,271~ = 3.0, *P* = 0.051). Sex remained independent after stratification (G~(2)~ = 4.38, *P* = 0.11). We again fit a linear model with all covariates and relevant interaction terms. Progranulin mRNA expression again was higher in males compared with females (log~2~FC = 0.12, +9%, *T*‐statistic = 4.4, *P* = 0.037), but age was no longer predictive (*T*‐statistic = 2.3, *P* = 0.13). We observed a significant effect based on diagnosis (*F* ~2,271~ = 17.9, *P* = 4.8\*10^−8^) but no interaction effects. Similar to the UCSF‐MAC cohort, we observed a significant increase (log~2~FC = 0.28, corresponding to +21%, TukeyHSD; *P* = 5.6\*10^−6^) in progranulin mRNA expression for AD patients compared with controls, and an increase (log~2~FC = 0.35, +27%, *P* = 6.4\*10^−7^) for MCI patients compared to controls (Fig. [1](#acn3560-fig-0001){ref-type="fig"}D).

We next validated these sex and age findings in a third dataset, the San Antonio Family Heart Study cohort (diagnosis was not relevant for this dataset). After stratifying to correct for collinearity between sex and smoking status, we excluded all samples under 30 years of age to more appropriately match mean cohort age with our other cohorts while still maintaining statistical power (*n* = 543, mean age = 49.7 years). We ensured no collinearity between age (*T*‐statistic = 1.06, *P* = 0.3) or smoking status (G~(2)~ = 4.48, *P* = 0.08) and sex and fit a linear model. We again found that progranulin was higher in males than females (log~2~FC = 0.07, +5%, *T*‐statistic = 4.8, *P* = 0.03) and found no correlation with age (*T*‐statistic = 0.04, *P* = 0.8). Interestingly, smoking status was an independent predictor of blood progranulin mRNA expression in this cohort, with a 6% GRN increase in smokers (log~2~FC = 0.08, *T*‐statistic = 4.5, *P* = 0.03).

Finally, we analyzed the ADNI patient cohort (*n* = 617), which is divided into asymptomatic controls, early MCI (eMCI), late MCI (lMCI, with regard to clinical disease progression), and AD. This cohort was initially confounded with significant collinearity between age (*F* ~3,696~ = 10.9, *P* = 5\*10‐7), sex (G~(3)~ = 11.1, *P* = 0.01) and diagnosis. We stratified and excluded samples (described in methods) until age (*F* ~3,613~ = 2.49, *P* = 0.06) and sex (G~(3)~ = 5.58, *P* = 0.13) were no longer collinear with diagnosis. However, a plate batch effect remained (G~(24)~ = 38.9, *P* = 0.03), which we corrected with the ComBat package. In this cohort, neither age nor sex were predictive of progranulin expression, and we did not observe differences in progranulin expression levels between diagnostic categories (*F* ~3,611~ = 0.31, *P* = 0.82, TukeyHSD post hoc *P* \> 0.05 for all comparisons; Fig. [1](#acn3560-fig-0001){ref-type="fig"}E).

### Effects of genotype on GRN expression {#acn3560-sec-0020}

Next, we genotyped samples from the UCSF‐MAC cohort for the risk‐associated rs5848 *GRN* variant. Homozygotes for the risk‐associated allele (T:T, *n* = 25) had a 12.3% decrease in progranulin mRNA expression compared with C:C carriers (log~2~FC = −0.19, Wilcoxon Rank sum test, *P* = 0.02) supporting an earlier report of decreased *GRN* mRNA levels in postmortem brain tissue of T:T genotype carriers.[36](#acn3560-bib-0036){ref-type="ref"} We also found that T‐allele carriers had significantly lower progranulin levels than C:C homozygotes (log~2~FC = −0.1, Welch, T~506~ = 2.24, *P* = 0.03; Fig. [2](#acn3560-fig-0002){ref-type="fig"}A). After ensuring there was no collinearity between the rs5848 genotype and sex (G‐statistic~1~ = 0.21, *P* = 0.65), we fit a linear model using sex and haplotype as an interaction term, but did not observe any significant interaction in our data. Additionally, using a Fisher\'s exact test, we observed an enrichment of T‐genotype carriers in the AD population compared with controls, which did not reach statistical significance (OR = 1.46, 95% CI = 0.95--2.38, *P* = 0.09). Thus, it is noteworthy that AD patients on average still have elevated progranulin gene expression despite the overrepresentation of rs5848 T‐allele carriers (associated with lower progranulin levels) in the AD patient population.

![Common AD‐associated genetic variants and *GRN* mRNA expression in peripheral blood. (A) Progranulin gene expression is lower in rs5848 risk allele carriers (C:T or T:T genotypes) compared with low‐risk genotype (C:C). UCSF‐MAC cohort, Welch\'s *t*‐test. (B) Progranulin gene expression is higher in APOE risk allele (E4) carriers (homozygote or heterozygote) compared with low‐risk haplotypes (E2 or E3 carriers). UCSF‐MAC cohort, Welch\'s *t*‐test. (A‐B) standard boxplot representing median and IQR, whiskers represent 1.5 IQR greater or less than the upper and lower quartile. \**P* \< 0.05, \*\**P* \< 0.01.](ACN3-5-616-g002){#acn3560-fig-0002}

We also studied the relationship between *GRN* gene expression levels and the AD risk‐associated APOE haplotype.[37](#acn3560-bib-0037){ref-type="ref"} We observed a significant effect of the APOE haplotype on progranulin levels in the UCSF‐MAC cohort across diagnostic categories, with progranulin mRNA levels significantly higher in E4 risk allele carriers compared with E2/E3 haplotypes (log~2~FC = 0.12, +9%, Welch, *T* ~(441)~ = 2.82 *P* = 0.005, Fig. [2](#acn3560-fig-0002){ref-type="fig"}B). However, there was also significant collinearity between APOE haplotype and disease status; the E4 haplotype was significantly enriched in AD patients (Fisher\'s exact test, OR = 4.83, *P* = 6.3\*10^−11^) compared with controls, confounding our results.

Therefore, we attempted to estimate the independent relationship between APOE haplotype and *GRN* expression. After removing the effects of diagnosis as a confound using a parametric empirical Bayesian estimator (ComBat), we still observed significantly higher progranulin gene expression levels in ApoE4 haplotype carriers (log~2~FC = 0.08, Welch *T*‐test, *P* = 0.04), suggesting that APOE4 genotype might function as a trans expression quantitative trait locus (eQTL) controlling *GRN* expression. We validated this finding in the Genotype‐Tissue Expression consortium dataset (GTEx).[38](#acn3560-bib-0038){ref-type="ref"} Analysis of rs429358 SNP (minor C‐allele tags the APOE4 haplotype) and RNA‐seq data from 328 samples revealed a significant association between expression and genotype (effect size = 0.12, *P* = 0.004) in whole blood. We checked the relationship between APOE4 carrier status and *GRN* expression in the ADNI dataset but failed to detect a difference in *GRN* expression between APOE4 carriers and controls (*T* ~(613)~ = 1.43, *P* = 0.15). We also performed the converse analysis in the UCSF‐MAC cohort. Using ComBat to remove the effect of APOE haplotype, we then modeled the effect of diagnosis on progranulin expression. We found that AD samples still had significantly higher progranulin expression (log~2~FC = 0.17, *T* ~(450)~ = 3.9, *P* = 0.0001) compared with controls suggesting that diagnosis predicts progranulin expression independent of APOE4 sample overrepresentation.

### GRN protein levels in CSF and plasma {#acn3560-sec-0021}

We next utilized ELISA to quantify progranulin protein levels in plasma (*n* = 266) and CSF (*n* = 80) in a subset of patients from the UCSF‐MAC cohort. After ensuring no collinearity with age (*F* ~2,263~ = 1.84, *P* = 0.16) and sex (G‐statistic~2~ = 2.32, *P*=0.31), we observed no correlation between plasma progranulin protein and gene expression in peripheral blood (Pearson\'s *r* = 0.065, df = 206, *P* = 0.35; Fig. [3](#acn3560-fig-0003){ref-type="fig"}A). However, we observed a sex dimorphism in our plasma data, with females across diagnostic categories having significantly higher progranulin protein levels than males (fold‐change = 0.07, Welch\'s *T* ~264~ = 2.14, *P* = 0.03, Fig. [3](#acn3560-fig-0003){ref-type="fig"}B) which recapitulates an earlier study,[16](#acn3560-bib-0016){ref-type="ref"} and is the opposite finding from our gene expression data, where males had higher *GRN* mRNA expression. We identified no correlation between age and plasma GRN protein levels (Pearson\'s *r* = 0.09, df = 264, *P* = 0.16). We next assessed the relationship between disease status and progranulin protein levels. In plasma, we found no difference between GRN protein levels across all disease categories (*F* ~2,263~ = 1.72, *P* = 0.18, Tukey\'s post hoc *P* \> 0.05 all comparisons; Fig. [3](#acn3560-fig-0003){ref-type="fig"}C) again replicating previous findings.[16](#acn3560-bib-0016){ref-type="ref"} We observed no correlation between progranulin levels in the CSF and in plasma (Pearson\'s *r* = 0.13, df = 63, *P* = 0.31; Fig. [3](#acn3560-fig-0003){ref-type="fig"}E). AD patients had statistically lower CSF progranulin levels than control subjects (*F* ~2,66~ = 3.45, *P* = 0.04, TukeyHSD *P* = 0.03 for AD vs. Control, Fig. [3](#acn3560-fig-0003){ref-type="fig"}D), confirming an earlier report.[39](#acn3560-bib-0039){ref-type="ref"} We observed no relationship between age or sex and progranulin levels in CSF.

![Progranulin protein levels by ELISA in plasma and cerebrospinal fluid (CSF). (A) Plasma progranulin protein levels are not correlated with gene expression within patients. *n* = 266, linear regression. (B) Females have significantly higher plasma GRN protein levels than males. Welch\'s *t*‐test. (C) Lack of difference in plasma GRN protein levels between AD,MCI, and control patients. Analysis of variance (AOV), Tukey\'s post hoc test. (D) AD patients have significantly lower CSF GRN protein levels than MCI and control patients. *n* = 80, AOV, Tukey\'s post hoc test. (E) Lack of correlation between plasma and CSF GRN protein levels. *n* = 80, linear regression. All analysis performed with the UCSF‐MAC cohort. (B**--**D) standard boxplot representing median and IQR, whiskers represent 1.5 IQR greater or less than the upper and lower quartile. (A,E) scatterplot with line of best‐fit. \**P* \< 0.05, *n*.s. *P* \> 0.05.](ACN3-5-616-g003){#acn3560-fig-0003}

### Analysis of GRN methylation status {#acn3560-sec-0022}

Finally, we analyzed DNA methylation at the *GRN* locus in a subset of subjects (AD patients \[n=128\] and controls \[n=227\]) from the UCSF‐MAC cohort. We found no correlation between *GRN* promoter CpG methylation and *GRN* expression (*T* ~(91)~ = 0.16, *r* = 0.02, *P* = 0.8) nor *GRN* gene body methylation and *GRN* gene expression (*T* ~(91)~ = 1.52, *r* = −0.16, *P* = 0.13). We next fit a linear model predicting methylation status, using all relevant predictors. Males had lower *GRN* promoter CpG methylation than females (Log~2~FC = 0.004, *T* ~(351)~ = 7.32, *P* = 0.007; Fig. [4](#acn3560-fig-0004){ref-type="fig"}C) but no differences in gene body methylation *T* ~(351)~ = 1.06, *P* = 0.3). Conversely, there was a negative correlation between age and *GRN* gene body methylation; methylation decreased significantly with age (*T* ~(351)~ = 62.8, *r* = ‐0.39, *P* = 3\*10^−14^; Fig. [4](#acn3560-fig-0004){ref-type="fig"}D). We identified no correlation between *GRN* promoter methylation and age (*T* ~(351)~ = 1.11, *r* = 0.05, *P* = 0.29) in agreement with Galimberti and colleagues.[40](#acn3560-bib-0040){ref-type="ref"} We identified no significant difference in methylation *β*‐values for either the *GRN* promoter (*T* ~(351)~ = 0.07, *P* = 0.79) or gene body (*T* ~(351)~ = 0.17, *P* = 0.67) between AD and control patients (Fig. [4](#acn3560-fig-0004){ref-type="fig"}A,B).

![Analysis of *GRN* promoter and gene body DNA (CpG) methylation in DNA from peripheral blood. (A--B) lack of difference in promoter (A) or gene body (B) methylation between AD and control patients. *n* = 355, Welch\'s *t*‐test. (C) *GRN* promoter methylation is significantly lower in males compared with females across diagnostics categories. Welch\'s *t*‐test. (D) *GRN* gene body methylation decreases with age. Linear regression. All analysis performed with the UCSF‐MAC cohort. (A‐C) standard boxplot representing median and IQR, whiskers represent 1.5 IQR greater or less than the upper and lower quartile. (D) scatterplot with line of best‐fit. \*\**P* \< 0.01, n.s. *P*\>0.05.](ACN3-5-616-g004){#acn3560-fig-0004}

Discussion {#acn3560-sec-0023}
==========

We present here data indicating that patients with sporadic Alzheimer\'s disease have significantly increased progranulin mRNA in peripheral blood compared with controls. Additionally, we find that progranulin expression is significantly increased in patients with mild cognitive impairment. While we have replicated these findings in an independent patient cohort (AddNeuroMed), we failed to replicate them in the ADNI cohort. Of note, both our cohort and the AddNeuroMed cohort used Illumina microarray platforms while the ADNI gene expression data was run on an Affymetrix platform. We therefore hypothesize that this discrepancy may be a feature of Affymetrix probes, which may not sensitively or reliably detect changes in progranulin expression levels. This is supported by our additional failure to detect any correlation between progranulin expression and age, sex, or genotype in the ADNI dataset.

While we identified differences in mean progranulin expression between groups, our results indicate that progranulin cannot be used on its own as a sensitive or specific biomarker of disease. However, our results suggest that it should be possible to identify further differentially expressed genes that could perhaps then be incorporated into a diagnostic panel. Because peripheral blood can be drawn from living patients in the most basic clinical settings, this has broader clinical utility. Most saliently, this study represents the first association between peripheral progranulin expression and MCI to our knowledge, suggesting that progranulin may play an early role in AD pathogenesis.

Previous studies in mouse models of AD have found that the artificial increase in progranulin levels can slow disease progression including disrupting A*β* plaque deposition and neurotoxicity.[14](#acn3560-bib-0014){ref-type="ref"} Furthermore, loss‐of‐function mutations in the progranulin gene are risk factors for developing AD as well as other neurodegenerative disorders.[4](#acn3560-bib-0004){ref-type="ref"}, [6](#acn3560-bib-0006){ref-type="ref"}, [8](#acn3560-bib-0008){ref-type="ref"} Together these findings suggest that progranulin plays a primarily neuroprotective role, reactively modifying or guarding against neurodegenerative processes. Our data support this hypothesis. The small subset of patients with the rs5848 (T:T) haplotype had significantly lower progranulin levels and were also more likely to have AD, as expected.[7](#acn3560-bib-0007){ref-type="ref"}, [9](#acn3560-bib-0009){ref-type="ref"} However, AD patients in general had higher progranulin levels, especially when excluding haplotypes that directly lower progranulin expression and cause disease. This suggests that progranulin expression might increase as an effect rather than a cause of disease. It is also conceivable that undiscovered cis or trans eQTLs that control progranulin expression exist, and therefore modify risk for AD. For example, we identify the APOE haplotype as a possible trans eQTL that influences progranulin expression, independent of AD diagnosis.

If progranulin plays a functional role in AD pathogenesis, we would expect to ultimately observe changes in protein levels. However, analysis of our ELISA data failed to show a difference in progranulin protein levels between AD, MCI, and control patients, consistent with earlier reports.[16](#acn3560-bib-0016){ref-type="ref"} There was also no correlation between progranulin protein levels in plasma and CSF and no correlation between protein and gene expression.[39](#acn3560-bib-0039){ref-type="ref"} Our ELISA findings are entirely consistent with and replicate previous independent reports, indicating that our results are not the result of operational error or a technical artifact. One likely interpretation is that the current ELISA methodology fails to accurately detect subtle changes in plasma progranulin levels. The progranulin protein has complex posttranslational regulation, including glycosylation and variable cleavage into a variety of intermediaries as well as any of 8 final granulin products. These various protein configurations have myriad and often contradictory functions.[41](#acn3560-bib-0041){ref-type="ref"} In fact, the current ELISA used is specific for unprocessed progranulin.[30](#acn3560-bib-0030){ref-type="ref"} Given high antibody specificity and the diversity of progranulin end products, it is unlikely that ELISA can sensitively detect overall changes in specific forms of progranulin being expressed in AD, MCI, and controls; rather it is likely reflective of a particular subset of progranulin products.

Additionally, progranulin and granulins undergo complex spatial regulation with progranulin being shuttled to both the lysosome or excreted into the extracellular space. As such, the biological fluid and cellular components assayed have a large impact on progranulin measurements.[42](#acn3560-bib-0042){ref-type="ref"} This might explain the sex dimorphism discrepancy between our gene expression and ELISA data in addition to differences in progranulin cleavage and processing. ELISA, which measures extracellular fluid (plasma), may not be directly comparable to intracellular gene expression profiles. Nevertheless, the functional significance of possibly increased progranulin secretion in females versus relative intracellular retention in males requires further study.

Finally, our data suggest that blood progranulin gene expression is higher overall in males than in females. Our *GRN* methylation data also supports this finding, as males have reduced promoter methylation, suggesting a derepressed state primed for transcriptional activation. These data are intriguing considering that progranulin expression in rat hippocampus was found to be under the control of estrogen.[43](#acn3560-bib-0043){ref-type="ref"} Although there have been numerous studies describing sex dimorphisms in gene methylation in peripheral blood, these studies have failed to specifically identify progranulin.[44](#acn3560-bib-0044){ref-type="ref"}, [45](#acn3560-bib-0045){ref-type="ref"} Nevertheless, it is especially interesting to consider this sex dimorphism as women are twice as likely to develop AD as men. If progranulin indeed plays a protective role, increased endogenous progranulin expression in males might partly explain this phenomenon, and this might be mechanistically mediated by differences in progranulin promoter methylation.
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